Literature DB >> 20026957

The concept of addiction in law and regulatory policy related to pain management: a critical review.

Aaron M Gilson1.   

Abstract

OBJECTIVE: To present a critical appraisal of the present definitions of addiction-related terminology that appear in US laws and regulatory policies that apply to the prescription of controlled substances for pain management.
METHODS: To establish an appropriate context for existing policy definitions, a historical review was conducted of reports from the World Health Organization expert committees on addiction-related concepts, beginning in 1950. In addition, current World Health Organization and American Psychiatric Association diagnostic classification nomenclature were examined. Results from recent criteria-based evaluations of federal and state laws and regulatory policies containing addiction-related terminology also were referenced.
RESULTS: Numerous examples are provided to clarify how inaccurate understandings of the nature of addiction, which can be corroborated by archaic definitions in some states' laws, can impact treatment decisions and patient care. Finally, this article discusses terminological and treatment implications of such concepts as "risk mitigation" and "responsible prescribing", which are goals currently emphasized in the pain management field as principal means to reduce addiction to or abuse of prescription opioid medications. DISCUSSION: Although notable improvement has been achieved, policy content in some states has not kept pace with advancements in medical and scientific knowledge about the interface between pain management and addictive disease. Effective translation of addiction-related concepts into clinical practice remains an important objective for promoting public health related to treating pain and reducing non-medical use of opioids.

Entities:  

Mesh:

Year:  2010        PMID: 20026957     DOI: 10.1097/AJP.0b013e3181b12a2d

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  8 in total

Review 1.  Opioid formulations designed to resist/deter abuse.

Authors:  Robert B Raffa; Joseph V Pergolizzi
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

Review 2.  Induction of innate immune genes in brain create the neurobiology of addiction.

Authors:  F T Crews; Jian Zou; Liya Qin
Journal:  Brain Behav Immun       Date:  2011-03-21       Impact factor: 7.217

Review 3.  Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.

Authors:  Jean Bonhomme; Ruth S Shim; Richard Gooden; Dawn Tyus; George Rust
Journal:  J Natl Med Assoc       Date:  2012 Jul-Aug       Impact factor: 1.798

4.  Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Authors:  Perrine Roux; Maria A Sullivan; Julien Cohen; Lionel Fugon; Jermaine D Jones; Suzanne K Vosburg; Ziva D Cooper; Jeanne M Manubay; Shanthi Mogali; Sandra D Comer
Journal:  Pain       Date:  2013-05-07       Impact factor: 6.961

5.  Seeking prescription opioids from physicians for nonmedical use among people who inject drugs in a Canadian setting.

Authors:  Mary Clare Kennedy; Thomas Kerr; Kora DeBeck; Huiru Dong; M-J Milloy; Evan Wood; Kanna Hayashi
Journal:  Am J Addict       Date:  2016-05-03

6.  EMS runs for suspected opioid overdose: implications for surveillance and prevention.

Authors:  Amy Knowlton; Brian W Weir; Frank Hazzard; Yngvild Olsen; Junette McWilliams; Julie Fields; Wade Gaasch
Journal:  Prehosp Emerg Care       Date:  2013 Jul-Sep       Impact factor: 3.077

7.  Walking the party line: The growing role of political ideology in shaping health behavior in the United States.

Authors:  Mugur V Geana; Nathaniel Rabb; Steven Sloman
Journal:  SSM Popul Health       Date:  2021-10-23

8.  Chronic opioid therapy and opioid tolerance: a new hypothesis.

Authors:  Joel S Goldberg
Journal:  Pain Res Treat       Date:  2013-01-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.